In a recent clinical trial, Craft et al. [84] studied the feasibility and efficacy of IN insulin in persons with mild cognitive impairment and AD, finding no improvements in cognitive or functional benefits compared with placebo after 12 months of daily dose. The gene discussed is INS; the disease is Alzheimer disease.